<DOC>
	<DOCNO>NCT02584933</DOCNO>
	<brief_summary>The rollover study provide ceritinib patient currently receive treatment ceritinib within Novartis-sponsored study opinion investigator , would benefit continued treatment ceritinib .</brief_summary>
	<brief_title>Roll-over Study Allow Access Certinib ( LDK378 ) Patients Who Are Ceritinib Treatment Novartis-sponsored Study</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ceritinib</mesh_term>
	<criteria>Patient currently receive treatment ceritinib within Novartissponsored study fulfil requirement primary objective , opinion Investigator , would benefit continued treatment . Patient demonstrate compliance , assess investigator , parent study protocol requirement . Willingness ability comply schedule visit , treatment plan study procedure . Written inform consent obtain prior enrol rollover study receive study medication . If consent express writing , must formally document witnessed via independent trusted witness . Patient permanently prematurely discontinue ceritinib study treatment parent study due reason . Patient currently unresolved toxicity ceritinib dose interrupt parent study . Pregnant nursing ( lactate ) woman , pregnancy define state female conception termination gestation , confirm positive serum hCG laboratory test . Women childbearing potential , defined woman physiologically capable become pregnant , unless use highly effective method contraception dose 3 month afer stop ceritinib treatment . Sexually active male unless use condom intercourse take drug 3 month stop ceritinib father child least 3 month last dose treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>ALK</keyword>
	<keyword>Malignancies</keyword>
</DOC>